Clinical trial shows tumor-starving drug improves survival of mesothelioma

Peter Szlosarek, Professor of Medical Oncology at Queen Mary’s Barts Cancer Institute, presented his team’s results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc., at the American Association for Cancer Research Annual Meeting. The findings show that the new drug, called ADI-PEG20, extends the median survival of patients compared with current standard treatment. This moves the drug closer to final approval by the US Food and Drug Administration (FDA), an achievement that would represent the first such approval of a new chemotherapy drug for this disease in 15 years.

Study of interleukin-6 impact on organoids shows increase in radial glia cells

A team of medical researchers at the University of Tübingen’s Hertie Institute for Clinical Brain Research in Germany has found that exposing organoids at a certain stage of growth to interleukin-6 leads to an increase in radial glia cells, which may provide a hint as to why pregnant women who experience infections are more likely to deliver a child who develops autism.

Clarify on multiple gov’t spokespersons, Kampyongo asks Secretary to Cabinet

By NATION REPORTER

THE opposition has called on government to clarify the role of multiple spokespersons in government who are responding in un-coordinated and un-procedural manner to political issues.

Opposition Chief Whip Stephen Kampyongo has challenged Secretary to the Cabinet Patrick Kangwa to call is officers to order to enforce discipline in the manner that government responses are generated by officers whose designation did not merit them to speak on behalf of rightful authorities.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.